טוען...
Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia
BACKGROUND: Intimal hyperplasia remains the primary cause of vein graft failure for the 1 million yearly bypass procedures performed using human saphenous vein (HSV) grafts. This response to injury is caused in part by the harvest and preparation of the conduit. The use of Brilliant Blue FCF (FCF) r...
שמור ב:
| הוצא לאור ב: | J Vasc Surg |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5480606/ https://ncbi.nlm.nih.gov/pubmed/27763268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jvs.2015.02.028 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|